CRYL1

Across TCGA pan-cancer cohorts, CRYL1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CRYL1 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CRYL1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CRYL1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where CRYL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.511	0.308	<.001	96	view →
CCRCC	DFS	Tertile	III,IV	0.705	0.293	.002	56	view →
LUAD	DFS	Median	III,IV	0.238	0.804	<.001	15	view →
HNSC	OS	Median	All	1.000	0.484	.038	12	view →
UCEC	OS	Quartile	II,III,IV	0.634	1.000	.048	4	view →
LSCC	OS	Quartile	All	0.736	0.902	.028	3	view →
GBM	DFS	Median	All	0.558	0.783	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CRYL1–PDAC (DFS)

Open the PDAC breakdown →